발기부전(ED) 치료제 시장(2026-2030년)

The global erectile dysfunction (ed) drugs market is forecasted to grow by USD 1756.5 mn during 2025-2030, accelerating at a CAGR of 7.1% during the forecast period. The report on the global erectile dysfunction (ed) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising demand for erectile dysfunction drugs, rising awareness of erectile dysfunction drugs, high prevalence of conditions resulting in erectile dysfunction.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global erectile dysfunction (ed) drugs market is segmented as below:

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

By Product

• Oral drugs
• Topical drugs
• Others

By Type

• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • The Netherlands
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the presence of novel drug formulations in late stages of development as one of the prime reasons driving the global erectile dysfunction (ed) drugs market growth during the next few years. Also, expanding research for development of novel therapies and increasing otc abuse of drugs will lead to sizable demand in the market.

The report on the global erectile dysfunction (ed) drugs market covers the following areas:

• Global erectile dysfunction (ed) drugs market sizing
• Global erectile dysfunction (ed) drugs market forecast
• Global erectile dysfunction (ed) drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global erectile dysfunction (ed) drugs market vendors that include A. Menarini Industrie Farma, Aseric Pharma, Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Dong A Socio Holdings Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Lupin Ltd., Nippon Shinyaku Co. Ltd., Pfizer Inc., Sandoz Group AG, Sanofi SA, SK Chemicals Co. Ltd., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc., VIVUS LLC. Also, the global erectile dysfunction (ed) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Product
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Erectile Dysfunction (ED) Drugs Market 2020 - 2024
  • Historic Market Size - Data Table on Global Erectile Dysfunction (ED) Drugs Market 2020 - 2024 ($ million)
• 5.2 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.3 Product segment analysis 2020 - 2024
  • Historic Market Size - Product Segment 2020 - 2024 ($ million)
• 5.4 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 The Impact of AI on the Global Erectile Dysfunction (ED) Drugs Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Distribution Channel

• 8.1 Market segments
• 8.2 Comparison by Distribution Channel
• 8.3 Hospital pharmacy - Market size and forecast 2025-2030
• 8.4 Retail pharmacy - Market size and forecast 2025-2030
• 8.5 Online pharmacy - Market size and forecast 2025-2030
• 8.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Product

• 9.1 Market segments
• 9.2 Comparison by Product
• 9.3 Oral drugs - Market size and forecast 2025-2030
• 9.4 Topical drugs - Market size and forecast 2025-2030
• 9.5 Others - Market size and forecast 2025-2030
• 9.6 Market opportunity by Product
  • Market opportunity by Product ($ million)

10 Market Segmentation by Type

• 10.1 Market segments
• 10.2 Comparison by Type
• 10.3 Sildenafil - Market size and forecast 2025-2030
• 10.4 Tadalafil - Market size and forecast 2025-2030
• 10.5 Vardenafil - Market size and forecast 2025-2030
• 10.6 Avanafil - Market size and forecast 2025-2030
• 10.7 Others - Market size and forecast 2025-2030
• 10.8 Market opportunity by Type
  • Market opportunity by Type ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 UK - Market size and forecast 2025-2030
  • 12.4.2 Germany - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.4.7 Russia - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
  • 12.5.7 Singapore - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Australia - Market size and forecast 2025-2030
  • 12.6.2 Brazil - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 South Africa - Market size and forecast 2025-2030
  • 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising demand for erectile dysfunction drugs
  • Rising awareness of erectile dysfunction drugs
  • High prevalence of conditions resulting in erectile dysfunction
• 13.2 Market challenges
  • Availability of generics drugs
  • Side-effects of available drugs
  • Poor reimbursement scenario
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Presence of novel drug formulations in late stages of development
  • Expanding research for development of novel therapies
  • Increasing OTC abuse of drugs

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 A. Menarini Industrie Farma
  • A. Menarini Industrie Farma - Overview
  • A. Menarini Industrie Farma - Product / Service
  • A. Menarini Industrie Farma - Key offerings
  • SWOT
• 15.5 Aseric Pharma
  • Aseric Pharma - Overview
  • Aseric Pharma - Product / Service
  • Aseric Pharma - Key offerings
  • SWOT
• 15.6 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Product / Service
  • Aurobindo Pharma Ltd. - Key offerings
  • SWOT
• 15.7 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.8 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.9 Dong A Socio Holdings Co. Ltd.
  • Dong A Socio Holdings Co. Ltd. - Overview
  • Dong A Socio Holdings Co. Ltd. - Product / Service
  • Dong A Socio Holdings Co. Ltd. - Key offerings
  • SWOT
• 15.10 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.11 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.12 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.13 Nippon Shinyaku Co. Ltd.
  • Nippon Shinyaku Co. Ltd. - Overview
  • Nippon Shinyaku Co. Ltd. - Business segments
  • Nippon Shinyaku Co. Ltd. - Key offerings
  • Nippon Shinyaku Co. Ltd. - Segment focus
  • SWOT
• 15.14 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.15 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Product / Service
  • Sandoz Group AG - Key offerings
  • SWOT
• 15.16 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.17 SK Chemicals Co. Ltd.
  • SK Chemicals Co. Ltd. - Overview
  • SK Chemicals Co. Ltd. - Product / Service
  • SK Chemicals Co. Ltd. - Key news
  • SK Chemicals Co. Ltd. - Key offerings
  • SWOT
• 15.18 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Product / Service
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations